Literature DB >> 12583682

Effectiveness and cost comparison of two strategies for hepatitis B vaccination of schoolchildren.

Maryse Guay1, Anne-Marie Clouâtre, Manon Blackburn, Geneviève Baron, Philippe De Wals, Chantale Roy, Jean Desrochers, François Milord.   

Abstract

CONTEXT: In 1994, immunization against hepatitis B was implemented in schools in Quebec, targeting grade 4 students. In 1996-1997 and 1997-1998, one Local Community Service Centre (CLSC) replaced the school-based program in its district with vaccination offered in community clinics after school hours. The aim of the current study was to compare the effectiveness and costs of school-based and clinic-based programs.
METHODS: Vaccination coverage data were collected in the CLSC with the clinic-based program (CBP), and in three matched CLSCs with a school-based program (SBP), from 1994 to 2000. Surveys were conducted to estimate costs to parents, to schools and to CLSCs in 1997-1998.
RESULTS: With the implementation of the CBP, the vaccination coverage fell to 73%, compared with over 90% in the SBPs. Coverage increased to 90% when the CBP was abandoned. Costs to the CLSC were not much lower in the CBP. Societal costs were $63 per student vaccinated in the CBP, and < or = $40 in the SBPs.
CONCLUSION: Results demonstrate the advantage of a SBP over a CBP for the immunization of schoolchildren.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12583682      PMCID: PMC6980189     

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  19 in total

1.  Recommendations regarding interventions to improve vaccination coverage in children, adolescents, and adults. Task Force on Community Preventive Services.

Authors: 
Journal:  Am J Prev Med       Date:  2000-01       Impact factor: 5.043

2.  Vaccine-preventable diseases: improving vaccination coverage in children, adolescents, and adults. A report on recommendations from the Task Force on Community Preventive Services.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1999-06-18

3.  Comparative immunogenicity under field conditions of two recombinant hepatitis B vaccines in 8-10-year-old children.

Authors:  B Duval; N Boulianne; G De Serres; N Laflamme; P De Wals; R Massé; G Trudeau; G Delage; L Desjardins
Journal:  Vaccine       Date:  2000-02-14       Impact factor: 3.641

4.  Assessment of a universal, school-based hepatitis B vaccination program.

Authors:  S Dobson; D Scheifele; A Bell
Journal:  JAMA       Date:  1995-10-18       Impact factor: 56.272

5.  Vaccination against hepatitis B virus in Spain: a cost-effectiveness analysis.

Authors:  R Garuz; J L Torrea; J M Arnal; T Forcen; C Trinxet; F Anton; F Antoñanzas
Journal:  Vaccine       Date:  1997-10       Impact factor: 3.641

6.  Hepatitis B mass immunization of adolescents: a pilot study in a community.

Authors:  S Plaitano; L Sagliocca; A Mele; C Bove; D Protano; B Adamo; F Palumbo; M Cauletti; E Franco; P Pasquini
Journal:  Eur J Epidemiol       Date:  1993-05       Impact factor: 8.082

7.  Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis.

Authors:  M Krahn; A S Detsky
Journal:  Med Decis Making       Date:  1993 Jan-Mar       Impact factor: 2.583

8.  A hepatitis B vaccination program targeting adolescents.

Authors:  W M Cassidy; F J Mahoney
Journal:  J Adolesc Health       Date:  1995-10       Impact factor: 5.012

9.  A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis.

Authors:  B S Bloom; A L Hillman; A M Fendrick; J S Schwartz
Journal:  Ann Intern Med       Date:  1993-02-15       Impact factor: 25.391

10.  Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations.

Authors:  H S Margolis; P J Coleman; R E Brown; E E Mast; S H Sheingold; J A Arevalo
Journal:  JAMA       Date:  1995-10-18       Impact factor: 56.272

View more
  5 in total

1.  HPV vaccine: positive insights from universal adolescent HepB vaccination.

Authors:  J Claire Cameron; Lesley A Wallace; Syed Ahmed; Rina Duff; Martin Donaghy; David J Goldberg
Journal:  J Epidemiol Community Health       Date:  2007-12       Impact factor: 3.710

2.  Advice for Consideration of Quadrivalent (A, C, Y, W135) Meningococcal Conjugate Vaccine, for use by Provinces and Territories.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2010-01-26

Review 3.  Increasing Coverage of Appropriate Vaccinations: A Community Guide Systematic Economic Review.

Authors:  Verughese Jacob; Sajal K Chattopadhyay; David P Hopkins; Jennifer Murphy Morgan; Adesola A Pitan; John M Clymer
Journal:  Am J Prev Med       Date:  2016-02-01       Impact factor: 5.043

4.  Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.

Authors:  Michele Kohli; Donna Lawrence; Jennifer Haig; Andrea Anonychuk; Nadia Demarteau
Journal:  BMC Public Health       Date:  2012-10-13       Impact factor: 3.295

Review 5.  Patient reminder and recall interventions to improve immunization rates.

Authors:  Julie C Jacobson Vann; Robert M Jacobson; Tamera Coyne-Beasley; Josephine K Asafu-Adjei; Peter G Szilagyi
Journal:  Cochrane Database Syst Rev       Date:  2018-01-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.